



- (51) **International Patent Classification:**
A61K 39/395 (2006.01) G01N 33/574 (2006.01)
A61K 47/48 (2006.01)
- (21) **International Application Number:**
PCT/US2015/017171
- (22) **International Filing Date:**
23 February 2015 (23.02.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/942,796 21 February 2014 (21.02.2014) US
- (71) **Applicant:** STEMCENTRX, INC. [US/US]; 450 East Jamie Court, South San Francisco, California 94080 (US).
- (72) **Inventors:** WILLIAMS, Samuel; 3000 Monterey St., San Mateo, California 94403 (US). SAUNDERS, Laura; 170 King Street, Unit 809, San Francisco, California 94107 (US). LOVING, Kathryn A.; 1460 Olympus Ave., Berkeley, California 94708 (US).
- (74) **Agents:** MEIGS, Julie Broadus et al.; Womble Carlyle Sandridge & Rice, LLP, P.O. Box 7037, Atlanta, Georgia 30357-0037 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title:** ANTI-DLL3 ANTIBODIES AND DRUG CONJUGATES FOR USE IN MELANOMA**Binding Characteristics of Anti-DLL3 Antibodies**

(57) **Abstract:** Anti-DLL3 antibodies and antibody drug conjugates for use in the diagnosis and treatment of melanoma.

Clone	Bin	Domain	Affinity (nM)
SC16.4	F	EGF4	0.5 ^F
SC16.8	A	EGF5	0.5 ^F
SC16.10	E	EGF2	4.0 ^F
SC16.13	B	EGF2	2.0 ^B
SC16.15	G	N-terminal	0.5 ^B
SC16.25	C	N-terminal	0.2 ^B
SC16.34	D	DSL	0.2 ^B
SC16.39	I	EGF6	1.0 ^F
SC16.46	A	EGF1	0.5 ^F
SC16.51	H	N-terminal	2.0 ^F
SC16.56	D	DSL	1.0 ^B
SC16.65	B	EGF2	0.9 ^B
SC16.67	D	EGF3	0.5 ^F

^B Biacore; ^F ForteBio**FIG. 5**

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*